Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis
Gastroenterology and Hepatology from Bed to Bench,
Vol. 16 No. 1 (2023),
2 January 2023
https://doi.org/10.22037/ghfbb.v16i1.2685
Abstract
Aim: The aim of the present study was to conduct a meta-analysis of the frequency of isoniazid-induced liver injury (INH-ILI) in patients receiving isoniazid (INH) preventative therapy (IPT).
Background: The frequency of hepatotoxicity (drug-induced liver injury: DILI) of antituberculosis drugs has been studied, especially when INH, rifampin, and pyrazinamide are co-administered. However, little is known about the frequency of DILI in patients with latent tuberculosis infection (LTBI), where IPT is indicated.
Methods: We searched PubMed, Google Scholar, and the Cochrane Database of Systematic Reviews for studies reporting the frequency of INH-ILI in patients with IPT using one or more diagnostic indicators included in the criteria of the DILI Expert Working Group.
Results:
Thirty-five studies comprising a total of 22,193 participants were included. The overall average frequency of INH-ILI was 2.6% (95% CI, 1.7-3.7%). The mortality associated with INH-DILI was 0.02% (4/22193). Subgroup analysis revealed no significant differences in the frequency of INH-ILI in patients older or younger than 50 years, children, patients with HIV, candidates for liver, kidney, or lung transplant, or according to the type of study design.
Conclusion: The frequency of INH-ILI in patients receiving IPT is low. Studies on INH-ILI are needed where the current DILI criteria are used.
- isoniazid
- Latent tuberculosis
- drug induced liver injury
- adverse drug reaction
- liver injury
How to Cite
References
Unissa AN, Subbian S, Hanna LE, Selvakumar N. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol 2016;45:474–492.
WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. n.d.
Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WCM, van der Ven AJAM, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol 2008;23:192–202.
Mølhave M, Wejse C. Historical review of studies on the effect of treating latent tuberculosis. Int J Infect Dis 2020;92:31–36.
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935–952.
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89:806–815.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:2535.
Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. Chest 1991;99:465–471.
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89:806–815.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 2014;12:1495–1499.
Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010;8:18.
Mansfield KE, Sim J, Jordan JL, Jordan KP. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. Pain 2016;157:55–64.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med 2019;381:1333–1346.
Simkins J, Abbo LM, Camargo JF, Rosa R, Morris MI. Twelve-week rifapentine plus isoniazid versus 9-month isoniazid for the treatment of latent tuberculosis in renal transplant candidates. Transplantation 2017;101:1468–1472.
Yamin A, Bornstein E, Hensel R, Mohamed O, Kempker RR. Predictors of latent tuberculosis infection treatment after introduction of a new regimen: a retrospective cohort study at an inner city clinic. Open Forum Infect Dis 2016;3.
Young H, Wessolossky M, Ellis J, Kaminski M, Daly JS. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central Massachusetts. Clin Infect Dis 2009;49:424–427.
Ekochin LH, Manadan AM, Aggarwal R, Sequeira W, Block JA. Absence of transaminase elevation during concomitant methotrexate and isoniazid therapy. J Rheumatol 2009;36:2127.
Jahng AW, Tran T, Bui L, Joyner JL. Safety of Treatment of Latent Tuberculosis Infection in Compensated Cirrhotic Patients During Transplant Candidacy Period. Transplantation 2007;83:1557–1562.
Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis. Arch Intern Med 2006;166:1863.
McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis. Chest 2003;123:102–106.
Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640.
Sadaphal P, Astemborski J, Graham NMH, Sheely L, Bonds M, Madison A, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with mycobacterium tuberculosis. Clin Infect Dis 2001;33:1687–1691.
Chang S-H, Nahid P, Eitzman SR. Hepatotoxicity in children receiving isoniazid therapy for latent tuberculosis infection. J Pediatric Infect Dis Soc 2014;3:221–227.
Jiménez-Fuentes MA, de Souza-Galvao ML, Mila Augé C, Solsona Peiró J, Altet-Gómez MN. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. Int J Tuberc Lung Dis 2013;17:326–332.
Geijo MP, Herranz CR, Vaño D, García ÁJ, García M, Dimas JF. Pauta corta de isoniazida y rifampicina comparada con isoniazida para la infección latente de tuberculosis. Ensayo clínico aleatorizado. Enferm Infecc Microbiol Clin 2007;25:300-304.
Fernandez‐Villar A, Sopena B, Vazquez R, Ulloa F, Fluiters E, Mosteiro M, et al. Isoniazid Hepatotoxicity among Drug Users: The Role of Hepatitis C. Clin Infect Dis 2003;36:293–298.
Tortajada C, Martínez-Lacasa J, Sánchez F, Jiménez-Fuentes A, De Souza ML, García JF, et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis 2005;9:276–281.
Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet 2014;384:682–690.
Gray D, Nuttall J, Lombard C, Davies M -a., Workman L, Apolles P, et al. Low rates of hepatotoxicity in HIV-infected children on anti-retroviral therapy with and without isoniazid prophylaxis. J Trop Pediatr 2010;56:159–165.
Taylor AW, Mosimaneotsile B, Mathebula U, Mathoma A, Moathlodi R, Theebetsile I, et al. Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. Infect Dis Obstet Gynecol 2013;2013:1–5.
Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:1588–1598.
Stucchi RSB, Boin IFSF, Angerami RN, Zanaga L, Ataide EC, Udo EY. Is isoniazid safe for liver transplant candidates with latent tuberculosis? Transplant Proc 2012;44:2406–2410.
Leung CC, Law WS, Chang KC, Tam CM, Yew WW, Chan CK, et al. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest 2003;124:2112–2118.
Vikrant S, Agarwal SK, Gupta S, Bhowmik D, Tiwari SC, Dash SC, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis 2005;7:99–108.
Codecasa LR, Murgia N, Ferrarese M, Delmastro M, Repossi AC, Casali L, et al. Isoniazid preventive treatment: predictors of adverse events and treatment completion. Int J Tuberc Lung Dis 2013;17:903–908.
Chung SJ, Lee H, Koo GW, Min J-H, Yeo Y, Park DW, et al. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital. Sci Rep 2020;10:6462.
Noh CS, Kim H Il, Choi H, Kim Y, Kim C-H, Choi J-H, et al. Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older. Respir Med 2019;157:52–58.
Naqvi R, Naqvi A, Akhtar S, Ahmed E, Noor H, Saeed T, et al. Use of isoniazid chemoprophylaxis in renal transplant recipients. Nephrol Dial Transplant 2010;25:634–637.
Korayem GB, Alissa DA, AlSuhaibani NI, AlSwailem GS, AlShammari MA, Yaqoob I, et al. Empiric vs screening‐based use of isoniazid for tuberculosis prophylaxis: Safety and effectiveness in lung transplant recipients in Saudi Arabia. Transpl Infect Dis 2021;23.
Frésard I, Bridevaux P, Rochat T, Janssens J. Adverse effects and adherence to treatment of rifampicine 4 months vs isoniazid 6 months for latent tuberculosis. Swiss Med Wkly 2011.
Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006;62:423–429.
Sun H-Y, Huang Y-W, Huang W-C, Chang L-Y, Chan P-C, Chuang Y-C, et al. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicentre randomised controlled trial in Taiwan. Tuberculosis 2018;111:121–126.
Chan P-C, Yang C-H, Chang L-Y, Wang K-F, Lu B-Y, Lu C-Y, et al. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Int J Tuberc Lung Dis 2012;16:633–638.
Devrim İ, Olukman Ö, Can D, Dizdarer C. Risk Factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults. Chest 2010;137:737–738.
Gray EL, Goldberg HF. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection. Intern Med J 2016;46:281–287.
Mudzviti T, Shamu T, Chimbetete C, Munengerwa T, Bote S, Pascoe M. Tolerability of isoniazid preventive therapy in an HIV-infected cohort of paediatric and adolescent patients on antiretroviral therapy from a resource-limited setting: a retrospective cohort study. Drugs - Real World Outcomes 2019;6:37–42.
Menzies D, Long R, Trajman A, Dion M-J, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection. Ann Intern Med 2008;149:689.
Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013.
National Cancer Institute. Common terminology criteria for adverse events, version 2.0. Bethesda, MD, USA: NCI, 2003 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf. Accessed octubre 2022 n.d.
Holty J-EC, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: A systematic review and meta-analysis of individual patient data. Liver Transplant 2009;15:894–906.
Salpeter SR. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993;159:560–564.
Hosford JD, von Fricken ME, Lauzardo M, Chang M, Dai Y, Lyon JA, et al. Hepatotoxicity from antituberculous therapy in the elderly: A systematic review. Tuberculosis 2015;95:112–122.
Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, et al. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis 2015;19:1039–1044.
- Abstract Viewed: 27 times
- PDF Downloaded: 18 times
- Supplementary Downloaded: 6 times